Literature DB >> 2667610

Heterogeneity in radiation sensitivity within human primary tumour cell cultures as detected by the SCE assay.

P J Tofilon1, C M Vines, R E Meyn, J Wike, W A Brock.   

Abstract

The ability of the sister chromatid exchange (SCE) assay to detect heterogeneity in intrinsic radiation sensitivity was investigated. In order to identify tumour cell subpopulations, frequency histograms of cis-diamminedichloroplatinum (II) (cPt)-induced SCEs were generated and compared to those from cultures that had been irradiated 96 h before drug treatment. The results suggested that subpopulations with different radiosensitivities were present in nine of 18 human primary tumour cell cultures evaluated. When the effects of prior irradiation on the subsequent X-ray survival response and on cPt-induced SCE frequency histograms were compared, a good correlation was obtained between the two assays regarding the prediction of heterogeneity in radioresponse. These results suggest that primary cultures can contain both radiation-sensitive and radiation-resistant cells, and thus heterogeneity in intrinsic radiosensitivity may exist in human solid tumours.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2667610      PMCID: PMC2246981          DOI: 10.1038/bjc.1989.11

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Cell survival and recovery processes in Chinese hamster AA8 cells and in two radiosensitive clones.

Authors:  S C vanAnkeren; D Murray; P M Stafford; R E Meyn
Journal:  Radiat Res       Date:  1988-08       Impact factor: 2.841

2.  A model of growth kinetics of irradiated cultured cells.

Authors:  Y Okumura; Y Uchiyama
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1974-10

3.  New Giemsa method for the differential staining of sister chromatids.

Authors:  P Perry; S Wolff
Journal:  Nature       Date:  1974-09-13       Impact factor: 49.962

4.  Detection of heterogeneity in the chemosensitivity of 9L brain tumor cell lines to 1,3-bis (2-chloroethyl)-1-nitrosourea by the sister chromatid exchange assay.

Authors:  P J Tofilon; K T Wheeler; D F Deen
Journal:  Eur J Cancer Clin Oncol       Date:  1984-07

5.  Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy.

Authors:  B Fertil; E P Malaise
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-05       Impact factor: 7.038

6.  Cycle-dependent anticancer drug cytotoxicity in mammalian cells synchronized by centrifugal elutriation.

Authors:  R E Meyn; M L Meistrich; R A White
Journal:  J Natl Cancer Inst       Date:  1980-05       Impact factor: 13.506

7.  Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.

Authors:  K G Louie; B C Behrens; T J Kinsella; T C Hamilton; K R Grotzinger; W M McKoy; M A Winker; R F Ozols
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

8.  Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium.

Authors:  F L Baker; G Spitzer; J A Ajani; W A Brock; J Lukeman; S Pathak; B Tomasovic; D Thielvoldt; M Williams; C Vines
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

9.  Prediction of in vivo tumor response to chemotherapeutic agents by the in vitro sister chromatid exchange assay.

Authors:  P J Tofilon; I Basic; L Milas
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

10.  Effect of cell-cell interactions on drug sensitivity and growth of drug-sensitive and -resistant tumor cells in spheroids.

Authors:  P J Tofilon; N Buckley; D F Deen
Journal:  Science       Date:  1984-11-16       Impact factor: 47.728

View more
  1 in total

1.  Growth and radiosensitivity testing of human tumour cells using the adhesive tumour cell culture system.

Authors:  C S Parkins; G G Steel
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.